Flp-In™ T-REx™ Core Kit
Product Image
Invitrogen™

Flp-In™ T-REx™ Core Kit

El sistema Flp-In™ T-REx™ permite la generación de líneas celulares de mamíferos que exhiben una expresión inducible de tetraciclina deMás información
Have Questions?
Número de catálogoCantidad
K6500011 kit
Número de catálogo K650001
Precio (MXN)
-
Cantidad:
1 kit
El sistema Flp-In™ T-REx™ permite la generación de líneas celulares de mamíferos que exhiben una expresión inducible de tetraciclina de un gen de interés de una ubicación genómica específica.

Las características del sistema Flp-In™ T-REx™ incluyen:

•Una vez que se haya creado la línea celular anfitriona Flp-In™ T-REx™ que contiene el sitio FRT integrado, la generación subsiguiente de líneas celulares Flp-In™ T-REx™ que expresan genes de interés es rápida y eficiente.
• El sistema Flp-In™ T-REx™ permite la generación de líneas celulares estables inducibles e isogénicas.
• El sistema Flp-In™ T-REx™ permite una selección policlonal de líneas celulares de expresión estables.

Cree una línea celular anfitrionas para varias aplicaciones de expresión
Para generar la línea celular anfitrionas de Flp-In™ T-REx™ para la expresión genética, primero debe transferir secuencialmente una línea celular de mamíferos con pFRT/lacZeo y pcDNA6/TR y ambas deben integrarse aleatoria e independientemente en el mismo genoma anfitrión. El anterior contiene el sitio FRT (para la recombinación intermolecular homóloga) secuencia abajo del codón de inicio de la fusión lacZ-Zeocin™. Este último expresa constitutivamente el represor de tetraciclina, que le permitirá regular la actividad del promotor TetO2.

Integración dirigida y expresión regulada
El siguiente paso para generar la línea celular inducible es co-transfeccionar los vectores pOG44 y pcDNA5/FRT/TO, el último de los cuales contiene su gen de interés bajo el control de un promotor de CMV/TetO2 regulado por tetraciclina, en su línea celular huésped. La recombinación homóloga entre los sitios FRT en pcDNA5/FRT/TO y en el cromosoma de la célula anfitrión, catalizada por la recombinasa Flp expresada a partir de pOG44, genera líneas de células derivadas en las que el gen se ha integrado de forma estable en el cromosoma de la célula anfitrión. Estas células se pueden seleccionar y mantener mediante la resistencia de higromicina y blasticidina adquirida como consecuencia del evento de recombinación.

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Sistema constitutivo o inducibleInducible
Tipo de entregaTransfección
Para utilizar con (aplicación)Expresión regulada
Agente inductorTetraciclina
Tipo de productoKit básico Flp-In
Cantidad1 kit
Agente de selección (eucariótico)Zeocin™, blasticidina, higromicina
VectorpFRT
Método de clonaciónEnzimas de restricción/MCS
Línea de productosFlp-In, T-REx
PromotorCMV/TO
Etiqueta de proteínaSin etiquetar
Unit SizeEach
Contenido y almacenamiento
Cada kit contiene los siguientes componentes:
• pFRT/lacZeo: 20μg, liofilizado en TE
• pcDNA6/TR: 20μg, liofilizado en TE
• pOG44: 20μg, liofilizado en TE
• pcDNA5/FRT/TO: 20μg, liofilizado en TE
• pcDNA5/FRT/TO/CAT: 20μg, liofilizado en TE
•cebador directo CMV (21-mer): 2μg, liofilizado en TE
• cebador inverso BGH (18-mer): 2 μg, liofilizado en TE
• Tetraciclina: 5 g
El kit se envía a temperatura ambiente. Conserve los vectores y cebadores a -20°C. conservar la tetraciclina a 4°C, proteger de la luz.

Preguntas frecuentes

I performed the Flp-In reaction and obtained hygromycin-resistant clones which also turned out to be Zeocin antibiotic resistant and lacZ-positive. I am concerned that the Flp-In reaction has not worked. Can you explain what might be happening?

We have observed in-house that in cells where the FRT site has integrated into a very transcriptionally active locus in the host cell genome (seen more commonly in Flp-In CHO and Flp-In 293 cells but can also happen in Flp-In 3T3 cells and any other Flp-In host cell line), there is some "read-through" transcription and translation of the lacZ-Zeocin ORF subsequent to the Flp-In reaction, even though the lacZ-Zeocin ORF does not have a bonafide promoter and ATG. In such cases, the hygromycin-resistant clones would also be lacZ-positive and Zeocin antibiotic-resistant. To make sure that the integration is FRT site-specific and not random, we recommend doing a parallel control transfection with no pOG44 present. This should yield no surviving clones upon hygromycin selection, indicating that all the hygromycin-resistant clones obtained in the presence of pOG44 are indeed Flp recombinase-dependent and hence have the gene of interest integrated at the FRT site. Also, a Southern blot analysis of these clones will help verify that they do indeed have proper FRT integration of the gene of interest despite the expression of lacZ (although this is typically not necessary). After the Flp-In reaction, as long as you see hygromycin-resistant clones, we recommend that you select them and assay them for expression of your gene of interest.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I used the pcDNA5/FRT vector in your Flp-In 3T3 cell line and was initially able to express my gene of interest, but after a month or so, lost expression. Why is this?

The Flp-In 3T3 cell line is derived from NIH3T3 cells, which are mouse fibroblast cells. The CMV promoter is known to get silenced over time in murine cell lines and hence we would recommend using a Flp-In expression vector with a non-CMV promoter in these cells, such as the pEF5/FRT/V5-D-TOPO vector or the pEF5/FRT/V5-DEST vector.

I used the pFRT/lacZeo vector to generate my own Flp-In host cell line and then made my Flp-In expression cell line. I am seeing very poor expression of my gene of interest. Is there anything else I can try to improve expression?

Before giving up, we would suggest that you try using the pFRT/lacZeo2 vector to generate your host cell line. This vector contains a truncated version of the SV40 promoter driving the lacZ-Zeocin fusion. Use of this vector facilitates the isolation of clones that have integrated the vector near enhancer elements in the genome, thus resulting in higher levels of expression of the gene of interest.

What is the difference between the Jump-In and Flp-In systems?

The Jump-In system is PhiC31-integrase mediated and is a stable, targeted, and irreversible mammalian expression system. It consists of the Jump-In Fast system that involves a single integration step and the Jump-InTI (targeted integration) system that needs two integration steps, both of which are targeted and irreversible. In contrast, the Flp-In system is a stable, targeted mammalian expression system that is reversible. The first integration is random (integration of pFRT/lacZeo), and the second integration (integration of the Flp-In expression vector) is targeted but reversible.

Is multiple integration of the Flp-In expression construct possible? How do you screen for multiple integrants, and how stable is the Flp-In expression cell line?

In theory, one can get multiple integrations of the Flp-In expression construct—an FRT-specific integration event and a random, second-site integration. However, random integration is a relatively uncommon event. Limiting the amount of DNA in the transfection will reduce the chance of second-site integration. We have transfected 293 cells (lacking the FRT site) with the pcDNA5/FRT vector and have identified one potential second-site integrant after screening over 200 clones. DNA integrations can be detected by Southern blot. A single integrant will display a single band; double: two; triple: three, etc. We have maintained a number of Flp-In expression cell lines for over four months and have not observed any loss of the Flp-In expression construct, whether hygromycin selection was maintained or not.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

Citations & References (10)

Citations & References
Abstract
A dynamic switch between inhibitory and excitatory currents in a neuronal glutamate transporter.
Authors:Melzer N, Torres-Salazar D, Fahlke C,
Journal:Proc Natl Acad Sci U S A
PubMed ID:16365297
'Excitatory amino acid transporters (EAATs) terminate glutamatergic synaptic transmission and maintain extracellular glutamate concentrations in the central nervous system below excitotoxic levels. In addition to sustaining a secondary-active glutamate transport, EAAT glutamate transporters also function as anion-selective channels. Here, we report a gating process that makes anion channels associated with ... More
Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis.
Authors:Giese B, Au-Yeung CK, Herrmann A, Diefenbach S, Haan C, Küster A, Wortmann SB, Roderburg C, Heinrich PC, Behrmann I, Müller-Newen G,
Journal:J Biol Chem
PubMed ID:12878601
'Signal transduction through cytokine receptors is mediated mainly by non-covalently associated Jak tyrosine kinases. By confocal microscopy, the cytokine receptor gp130 and Jak1, fused with either yellow (YFP) or cyan (CFP) fluorescent protein, were found to be colocalized predominantly at intracellular vesicular structures and at the plasma membrane. Quantitative fluorescence ... More
Pattern of genes influenced by conditional expression of the transcription factors HNF6, HNF4alpha and HNF1beta in a pancreatic beta-cell line.
Authors:Thomas H, Senkel S, Erdmann S, Arndt T, Turan G, Klein-Hitpass L, Ryffel GU,
Journal:Nucleic Acids Res
PubMed ID:15520459
'Using the rat insulinoma cell line INS-1 we generated beta-cell clones that are most efficient for gene transfer, as they contain an FRT site for Flp recombinase-mediated, site-directed integration of a single copy transgene. Therefore, the gene-of-interest can be introduced by DNA transfection without the need to select individual cell ... More
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
Authors:Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR, Linehan WM, Schmidt LS, Zbar B,
Journal:Proc Natl Acad Sci U S A
PubMed ID:17028174
'Birt-Hogg-Dubé syndrome, a hamartoma disorder characterized by benign tumors of the hair follicle, lung cysts, and renal neoplasia, is caused by germ-line mutations in the BHD(FLCN) gene, which encodes a tumor-suppressor protein, folliculin (FLCN), with unknown function. The tumor-suppressor proteins encoded by genes responsible for several other hamartoma syndromes, LKB1, ... More
Discovery of the ergothioneine transporter.
Authors:Gründemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schömig E,
Journal:Proc Natl Acad Sci U S A
PubMed ID:15795384
'Variants of the SLC22A4 gene are associated with susceptibility to rheumatoid arthritis and Crohn''s disease. SLC22A4 codes for an integral membrane protein, OCTN1, that has been presumed to carry organic cations like tetraethylammonium across the plasma membrane. Here, we show that the key substrate of this transporter is in fact ... More